Protein Science, Vol 7, Issue 2 259-269, Copyright © 1998 by Cold Spring Harbor Laboratory Press

ARTICLE

Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling

T. PIIRONEN, B. O. VILLOUTREIX, C. BECKER, K. HOLLINGSWORTH, M. VIHINEN, D. BRIDON, X. QIU, J. RAPP, B. DOWELL, T. LOVGREN, K. PETTERSSON and H. LILJA
Department of Biotechnology, University of Turku, Turku, Finland

Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2), produced essentially by the prostate gland, are 237-amino acid monomeric proteins, with 79% identity in primary structure. Twenty-five anti-PSA monoclonal antibodies (Mabs) were studied for binding to a large array of synthetic linear peptides selected from computer models of PSA and hK2, as well as to biotinylated peptides covering the entire PSA sequence. Sixteen of the Mabs were bound to linear peptides forming four independent binding regions (I-IV). Binding region I was localized to amino acid residues 1-13 (identical sequence for PSA and hK2), II (a and b) was localized to residues 53-64, III (a and b) was localized to residues 80-91 (= kallikrein loop), and IV was localized to residues 151-164. Mabs binding to regions I and IIa were reactive with free PSA, PSA-ACT complex, and with hK2; Mabs binding to regions IIb, IIIa, and IV were reactive with free PSA and PSA-ACT complex, but unreactive with hK2; Mabs binding to region IIIb detected free PSA only. All Mabs tested (n = 7) specific for free PSA reacted with kallikrein loop (binding region IIIb). The presence of Mabs interacting with binding region I did not inhibit the catalytic activity of PSA, whereas Mabs interacting with other binding regions inhibited the catalysis. Theoretical model structures of PSA, hK2, and the PSA-ACT complex were combined with the presented data to suggest an overall orientation of PSA with regard to ACT.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Berglund, J. Andrade, J. Odeberg, and M. Uhlen The epitope space of the human proteome Protein Sci., April 1, 2008; 17(4): 606 - 613. [Abstract] [Full Text] [PDF]

				R. C. Bast Jr., H. Lilja, N. Urban, D. L. Rimm, H. Fritsche, J. Gray, R. Veltri, G. Klee, A. Allen, N. Kim, et al. Translational Crossroads for Biomarkers Clin. Cancer Res., September 1, 2005; 11(17): 6103 - 6108. [Abstract] [Full Text] [PDF]

				Y. Baumgart, A. Otto, A. Schafer, E. Usbeck, C. Cott, A. Schott, M. Tornack, A. Wenzel, A. Mossie, and G. Birkenmeier Characterization of Novel Monoclonal Antibodies for Prostate-Specific Antigen (PSA) with Potency to Recognize PSA Bound to {alpha}2-Macroglobulin Clin. Chem., January 1, 2005; 51(1): 84 - 92. [Abstract] [Full Text] [PDF]

				V. Vaisanen, S. Eriksson, K. K. Ivaska, H. Lilja, M. Nurmi, and K. Pettersson Development of Sensitive Immunoassays for Free and Total Human Glandular Kallikrein 2 Clin. Chem., September 1, 2004; 50(9): 1607 - 1617. [Abstract] [Full Text] [PDF]

				U.-H. Stenman Standardization as a Private Enterprise Clin. Chem., April 1, 2003; 49(4): 535 - 536. [Full Text] [PDF]

				J. Leinonen, P. Wu, and U.-H. Stenman Epitope Mapping of Antibodies against Prostate-specific Antigen with Use of Peptide Libraries Clin. Chem., December 1, 2002; 48(12): 2208 - 2216. [Abstract] [Full Text] [PDF]

				P. Niemela, J. Lovgren, M. Karp, H. Lilja, and K. Pettersson Sensitive and Specific Enzymatic Assay for the Determination of Precursor Forms of Prostate-specific Antigen after an Activation Step Clin. Chem., August 1, 2002; 48(8): 1257 - 1264. [Abstract] [Full Text] [PDF]

				T. Soukka, J. Paukkunen, H. Harma, S. Lonnberg, H. Lindroos, and T. Lovgren Supersensitive Time-resolved Immunofluorometric Assay of Free Prostate-specific Antigen with Nanoparticle Label Technology Clin. Chem., July 1, 2001; 47(7): 1269 - 1278. [Abstract] [Full Text] [PDF]

				T. Piironen, M. Nurmi, K. Irjala, O. Heinonen, H. Lilja, T. Lovgren, and K. Pettersson Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing Clin. Chem., April 1, 2001; 47(4): 703 - 711. [Abstract] [Full Text] [PDF]

				H. Harma, T. Soukka, and T. Lovgren Europium Nanoparticles and Time-resolved Fluorescence for Ultrasensitive Detection of Prostate-specific Antigen Clin. Chem., March 1, 2001; 47(3): 561 - 568. [Abstract] [Full Text] [PDF]

				P. Nurmikko, V. Vaisanen, T. Piironen, S. Lindgren, H. Lilja, and K. Pettersson Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA Clin. Chem., October 1, 2000; 46(10): 1610 - 1618. [Abstract] [Full Text] [PDF]

				C. Becker, T. Piironen, J. Kiviniemi, H. Lilja, and K. Pettersson Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum Clin. Chem., February 1, 2000; 46(2): 198 - 206. [Abstract] [Full Text] [PDF]

				S. Michel, G. Deleage, J.-P. Charrier, J. Passagot, N. Battail-Poirot, G. Sibai, M. Jolivet, and C. Jolivet-Reynaud Anti-Free Prostate-specific Antigen Monoclonal Antibody Epitopes Defined by Mimotopes and Molecular Modeling Clin. Chem., May 1, 1999; 45(5): 638 - 650. [Abstract] [Full Text] [PDF]